BioMarin Anticipates FDA Approval Of Phenoptin In Late 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Pricing strategies for the orphan drug are under development as BioMarin plans a 20-rep sales force expansion, firm tells “The Pink Sheet” DAILY.